A sunscreen formulated for the Canadian market doesn’t automatically clear the U.S. market, and vice versa. Canada sorts sunscreens into two regulatory pathways based on their active ingredients, while the U.S. treats every sunscreen as a drug from the outset, regardless of its ingredients. The two systems ask different questions, require different data, and use different label language, which means a company entering both markets is really running two separate compliance projects under one product.
QSS works with companies bringing sunscreen and other UV protection products into both the Canadian and U.S. markets, and classification is usually where the process either moves smoothly or stalls. This guide walks through how each country regulates sunscreen, where the two frameworks diverge, and a 2026 update to the U.S. monograph that changes what’s available to formulators for the first time in over 20 years.
How Health Canada Regulates Sunscreen
Health Canada classifies sunscreens as either Natural Health Products (NHPs) or non-prescription drugs, and the deciding factor is the active ingredient. A product formulated with mineral or naturally derived UV filters, such as titanium dioxide, zinc oxide, or p-aminobenzoic acid, typically qualifies for the NHP pathway and needs a Natural Product Number (NPN) before it can be sold. A product that relies on synthetic filters such as avobenzone, oxybenzone, or octinoxate falls under the non-prescription drug pathway instead, which requires a Drug Identification Number (DIN).
The distinction matters well beyond paperwork. NHP and drug submissions go through different review processes, different timelines, and different ongoing compliance obligations once the product is on the market. QSS typically recommends confirming which pathway a formulation falls under before finalizing packaging or marketing claims, since a late reclassification can mean relabelling an entire product line.
What Canadian Sunscreen Labels Must (and Can’t) Say
Every sunscreen sold in Canada needs a label statement to the effect of “helps prevent sunburn,” along with its SPF value clearly displayed. A “Broad Spectrum SPF” claim is only permitted if testing demonstrates a critical wavelength of at least 370 nm, so that claim carries a specific testing burden behind it.
Health Canada also draws firm lines around what a label can’t say. A product can’t be marketed as a “sunblock” or otherwise imply it fully blocks UV exposure, and it can’t claim to prevent cancer or photo-aging, since those are treatment or prevention claims the product hasn’t been reviewed to support. Labels also need to be bilingual, carry the DIN or NPN, and include usage instructions and any required warnings. These aren’t formalities; a label that oversteps its claims is one of the more common reasons Health Canada flags a product post-market.
How the FDA Regulates Sunscreen
The U.S. takes a simpler starting position: every sunscreen is an over-the-counter drug, full stop, because a UV-protection claim meets the legal definition of a drug under U.S. law. That single classification decision shapes everything downstream, since it means every sunscreen sold in the U.S. must meet the FDA’s OTC Sunscreen Monograph, known as Monograph M020 (21 CFR Part 352), rather than being evaluated on a case-by-case basis.
Monograph M020 spells out which active ingredients are approved, at what concentrations, and what testing a product needs to support its label claims. Ingredients like zinc oxide, titanium dioxide, and several chemical filters, including avobenzone, are already listed, which means a product using only those ingredients can be marketed without a separate FDA submission as long as it meets the monograph’s conditions. Manufacturers also need a National Drug Code (NDC) labeler code from the FDA before the product goes to market.
When a New Drug Application Is Required
Some formulations don’t fit neatly inside the monograph, and that’s where the process gets longer. A company that wants to use an active ingredient the monograph doesn’t list, or make a label claim the monograph doesn’t cover, has to file a full New Drug Application under 21 CFR Part 314. That route calls for clinical safety and efficacy data and typically takes considerably longer to clear than a monograph-compliant product does. QSS generally advises checking a formulation against the current monograph early, since discovering an ingredient falls outside it midway through development can add months to a launch timeline.
The 2026 Monograph Update Changes What’s Available
On June 10, 2026, the FDA issued Final Administrative Order OTC000039, adding bemotrizinol to Monograph M020 at concentrations up to 6 percent. It’s the first new active ingredient added to the U.S. sunscreen monograph since the late 1990s, and it takes effect August 9, 2026. Once the order takes effect, sunscreen products containing bemotrizinol can be marketed under the monograph without a separate NDA, provided they meet the order’s conditions on concentration, permitted ingredient combinations, and dosage form.
The update is a meaningful signal on its own. FDA’s monograph process has moved slowly for decades, and this order suggests the streamlined review process introduced under the CARES Act is starting to clear ingredient requests that had been pending for years. Companies with a sunscreen ingredient currently under FDA review, or considering a submission, have reason to watch for further monograph amendments following this one.
Where the Two Frameworks Actually Diverge
The practical gap between these two systems shows up most clearly when a company tries to launch the same formulation in both countries. A mineral-only sunscreen built for the Canadian NHP pathway will usually also qualify as a US monograph drug, since most mineral filters are already FDA-approved ingredients. A sunscreen relying on a synthetic filter not listed in Monograph M020 is a different story. It may already hold a Canadian DIN and be selling well domestically, and still need a full NDA to enter the US market, with all the time and data that involves.
Quality Smart Solutions (QSS) sees this gap catch companies most often when US expansion gets added to the plan after a product has already launched in Canada, rather than being built into the formulation strategy from the start. Confirming both countries’ requirements before finalizing a formulation is almost always faster than adapting an existing product once it’s already in production.
Frequently Asked Questions
How do I know if my sunscreen needs a DIN or an NPN in Canada?
The active ingredients decide it. If the formulation uses only mineral or naturally derived UV filters, it typically qualifies for the NHP pathway and needs an NPN. If it contains synthetic filters such as avobenzone or oxybenzone, it falls under the non-prescription drug pathway and needs a DIN instead. Confirming this early avoids relabelling or resubmitting later in the process.
Why can't a sunscreen be marketed as "sunblock" in Canada?
Health Canada doesn’t allow label language that implies a product completely blocks UV exposure, since no sunscreen achieves 100 percent protection. The same restriction applies to claims about preventing cancer or photo-aging, since those go beyond what the product’s approved testing supports. Using restricted language on a label is a common trigger for post-market compliance action.
Is sunscreen regulated as a cosmetic in the US the way it can be in some other countries?
No. The FDA regulates sunscreen exclusively as an over-the-counter drug because a UV protection claim meets the legal definition of a drug under US law, regardless of how the product is marketed elsewhere. That means every US sunscreen has to meet Monograph M020’s requirements or go through a full NDA, with no cosmetic-only pathway available.
What actually changes with the FDA's June 2026?
Starting August 9, 2026, sunscreen products containing bemotrizinol at concentrations up to 6 percent can be marketed under Monograph M020 without a separate New Drug Application, as long as they meet the order’s conditions on concentration, combinations, and dosage form. It’s the first new active ingredient added to the US monograph in over two decades, which makes it a meaningful expansion of what’s readily available to formulators.
Does holding a Canadian DIN help at all when entering the US market?
Not directly. Canadian and US sunscreen approvals are entirely separate systems, so a Canadian DIN doesn’t carry any weight with the FDA. A product still needs to meet Monograph M020’s requirements, or go through a full NDA if it doesn’t, regardless of its regulatory status in Canada.
Key Takeaways
- Canada classifies sunscreen as either an NHP (NPN) or a non-prescription drug (DIN), based on the active ingredients used.
- The US regulates all sunscreen as an OTC drug under Monograph M020, with a full NDA required for ingredients or claims not covered by the monograph.
- Canadian labels must be bilingual and can’t use “sunblock,” “cancer prevention,” or “anti-aging” language.
- U.S. labels require a Drug Facts panel, SPF rating, and reapplication instructions.
- The FDA’s June 2026 order adding bemotrizinol to Monograph M020 is the first new monograph ingredient in over 20 years, effective August 9, 2026.
- A product’s Canadian classification doesn’t carry over to the US, so cross-border launches require both frameworks to be confirmed early.
Conclusion
Sunscreen compliance in Canada and the US comes down to more than one decision. Classification sets the starting point, but labelling language, testing requirements, and monograph status all shape whether a product can legally reach shelves in either market, and staying current with changes like the FDA’s 2026 monograph update matters just as much as getting the initial classification right. Companies that confirm both frameworks early, rather than adapting a finished product after the fact, tend to move through market entry with far fewer surprises.
Quality Smart Solutions (QSS) works with companies at every stage of this process, from DIN applications and Canadian cosmetic notifications to U.S. drug registration and NDC codes. If your team is weighing NPN or DIN classification, preparing a US monograph submission, or figuring out where a formulation stands under the FDA’s new bemotrizinol order, we’re happy to walk through where your product fits. Contact us to talk through next steps.
